Trump's Plan to Cut Drug Prices Was to Buy From Canada. Canada Said No.

By The Decision Room

Community Score: 50% | 1.2K views | 4w

0 community ratings: null thumbs up, null thumbs down

Americans pay up to ten times more for insulin than Canadians living minutes across the border — and Donald Trump's signature plan to lower U.S. drug prices depends entirely on importing from, or matching the prices of, the very country he keeps tariffing. There's just one problem: Canada already said no. In this episode, James Wren breaks down why U.S. drug prices are the highest on Earth, how Canada's price regulation made the same medicine a fraction of the cost, why Trump's two-door plan (import from Canada / Most-Favored-Nation pricing) runs into a wall Canada built on purpose — and the honest case on every side, including why the real fix was always at home. 🤖 This video was created with AI assistance — AI-generated voice, AI-assisted research and writing. Real sources, real analysis. Sources include: RAND Corporation / U.S. HHS, Mayo Clinic Proceedings, the Patented Medicine Prices Review Board, Health Canada (Safeguarding the Drug Supply regulations), the FDA, and U.S. Con

Tags: drug prices, insulin price, trump drug prices, prescription drugs, most favored nation drug pricing, canada us trade war, trump tariffs canada, mark carney, big pharma, the decision room, canada news today, world news, insulin, canada news, health care, local news, trade war, news, tariffs, mark carney trump